A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709)
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Community Cancer Institute — Clovis, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (47 Sites)
Showing the first 25 of 47 sites.
- Community Cancer Institute — Clovis, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- University of Iowa — Iowa City, Iowa
- John Theurer Cancer Center — Hackensack, New Jersey
- Local Institution - 0006 — New York, New York
- Local Institution - 0002 — New York, New York
- Providence Cancer Center Oncology and Hematology Care- Eastside — Portland, Oregon
- Local Institution - 0063 — Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- Houston Methodist Hospital — Houston, Texas
- Blacktown Hospital — Blacktown, New South Wales
- Liverpool Hospital — Liverpool, New South Wales
- Princess Alexandra Hospital — Brisbane, Queensland
- Cabrini Hospital - Malvern — Malvern, Victoria
- St Vincent's Hospital — Melbourne, Victoria
- One Clinical Research — Nedlands, Western Australia
- Cross Cancer Institute — Edmonton, Alberta
- Local Institution - 0030 — Vancouver, British Columbia
- Hamilton Health Sciences-Juravinski Cancer Centre — Hamilton, Ontario
- Local Institution - 0009 — Toronto, Ontario
- Centre Hospitalier de luniversite de Montreal — Montreal, Quebec
- Local Institution - 0016 — Ottawa,
- Local Institution - 0044 — Ulm, Baden-Wurttemberg
- Universitaetsklinikum Carl Gustav Carus Dresden-University Cancer Center Early Clinical Trial Unit — Dresden,
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cervical Cancer
- SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study) — Ouagadougou,
- Dostarlimab and Cobolimab in Advanced Cervical Cancer — Boston, Massachusetts
- International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer — Liège,
- Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement — Houston, Texas
- Sexual Health Empowerment for Women's Health — Kansas City, Missouri
- Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique — Houston, Texas
Explore by condition: All Cervical Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.